Page 67 - Read Online

Estévez-Arias et al. J Transl Genet Genom 2022;6:333-52 https://dx.doi.org/10.20517/jtgg.2022.04 Page 351

94. Rauchenzauner M, Frühwirth M, Hecht M, Kofler M, Witsch-Baumgartner M, Fauth C. A Novel variant in the HINT1 gene in a girl
with autosomal recessive axonal neuropathy with neuromyotonia: thorough neurological examination gives the clue. Neuropediatrics
2016;47:119-22. DOI PubMed
95. Caetano JS, Costa C, Baets J, et al. Autosomal recessive axonal neuropathy with neuromyotonia: a rare entity. Pediatr Neurol
2014;50:104-7. DOI PubMed
96. Laššuthová P, Brožková DŠ, Krůtová M, et al. Mutations in HINT1 are one of the most frequent causes of hereditary neuropathy
among Czech patients and neuromyotonia is rather an underdiagnosed symptom. Neurogenetics 2015;16:43-54. DOI
97. Kontogeorgiou Z, Voudommatis C, Kartanou C, et al. HINT1-related neuropathy in Greek patients with Charcot-Marie-Tooth
disease. J Peripher Nerv Syst 2021;26:444-8. DOI PubMed
98. Chou TF, Sham YY, Wagner CR. Impact of the C-terminal loop of histidine triad nucleotide binding protein1 (Hint1) on substrate
specificity. Biochemistry 2007;46:13074-9. DOI PubMed
99. Ouvrier R, Mcleod J, Morgan G, Wise G, Conchin T. Hereditary motor and sensory neuropathy of neuronal type with onset in early
childhood. J Neurol Sci 1981;51:181-97. DOI PubMed
100. Lee M, Park CH, Chung HK, et al. Cerebral white matter abnormalities in patients with charcot-marie-tooth disease. Ann Neurol
2017;81:147-51. DOI PubMed
101. Larrea D, Pera M, Gonnelli A, et al. MFN2 mutations in Charcot-Marie-Tooth disease alter mitochondria-associated ER membrane
function but do not impair bioenergetics. Hum Mol Genet 2019;28:1782-800. DOI
102. Pipis M, Feely SME, Polke JM, et al. Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study.
Brain 2020;143:3589-602. DOI PubMed PMC
103. Bombelli F, Stojkovic T, Dubourg O, et al. Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic
features. JAMA Neurol 2014;71:1036-42. DOI PubMed
104. Feely SM, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology
2011;76:1690-6. DOI PubMed PMC
105. Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science 2012;337:1062-5. DOI PubMed PMC
106. Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 2008;456:605-10. DOI PubMed
107. Koshiba T, Detmer SA, Kaiser JT, Chen H, McCaffery JM, Chan DC. Structural basis of mitochondrial tethering by mitofusin
complexes. Science 2004;305:858-62. DOI PubMed
108. Chen H, Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol
Genet 2009;18:R169-76. DOI PubMed PMC
109. Leal NS, Schreiner B, Pinho CM, et al. Mitofusin-2 knockdown increases ER-mitochondria contact and decreases amyloid β-peptide
production. J Cell Mol Med 2016;20:1686-95. DOI PubMed PMC
110. Filadi R, Greotti E, Turacchio G, Luini A, Pozzan T, Pizzo P. Mitofusin 2 ablation increases endoplasmic reticulum-mitochondria
coupling. Proc Natl Acad Sci USA 2015;112:E2174-81. DOI PubMed PMC
111. Merkwirth C, Langer T. Mitofusin 2 builds a bridge between ER and mitochondria. Cell 2008;135:1165-7. DOI PubMed
112. Vielhaber S, Debska-Vielhaber G, Peeva V, et al. Mitofusin 2 mutations affect mitochondrial function by mitochondrial DNA
depletion. Acta Neuropathol 2013;125:245-56. DOI PubMed
113. Amiott EA, Lott P, Soto J, et al. Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin
2 mutations. Exp Neurol 2008;211:115-27. DOI PubMed PMC
114. Loiseau D, Chevrollier A, Verny C, et al. Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A disease. Ann Neurol
2007;61:315-23. DOI PubMed
115. Chandhok G, Lazarou M, Neumann B. Structure, function, and regulation of mitofusin-2 in health and disease. Biol Rev Camb Philos
Soc 2018;93:933-49. DOI PubMed PMC
116. Westermann B. Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol 2010;11:872-84. DOI PubMed
117. El Fissi N, Rojo M, Aouane A, et al. Mitofusin gain and loss of function drive pathogenesis in. Drosophila 2018;19:e45241. DOI
PubMed PMC
118. Tomaselli PJ, Kapoor M, Cortese A, Polke JM, Rossor AM, Reilly MM. Severe cognitive impairment in a patient with CMT2A. J
Peripher Nerv Syst 2018;23:147-8. DOI PubMed
119. Filadi R, Pendin D, Pizzo P. Mitofusin 2: from functions to disease. Cell Death Dis 2018;9:330. DOI PubMed PMC
120. Otani Y, Ohno N, Cui J, Yamaguchi Y, Baba H. Upregulation of large myelin protein zero leads to Charcot-Marie-Tooth disease-like
neuropathy in mice. Commun Biol 2020;3:121. DOI PubMed PMC
121. Jerath NU, Shy ME. Hereditary motor and sensory neuropathies: Understanding molecular pathogenesis could lead to future
treatment strategies. Biochim Biophys Acta 2015;1852:667-78. DOI PubMed
122. Shy ME, Jáni A, Krajewski K, et al. Phenotypic clustering in MPZ mutations. Brain 2004;127:371-84. DOI PubMed
123. Raasakka A, Ruskamo S, Kowal J, et al. Molecular structure and function of myelin protein P0 in membrane stacking. Sci Rep
2019;9:642. DOI PubMed PMC
124. Luo X, Sharma D, Inouye H, et al. Cytoplasmic domain of human myelin protein zero likely folded as beta-structure in compact
myelin. Biophys J 2007;92:1585-97. DOI PubMed PMC
125. Bai Y, Wu X, Brennan KM, et al. Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease
type 1B. Ann Clin Transl Neurol 2018;5:445-55. DOI PubMed PMC